Staphylococcal Infections Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, August 2011, Pages: 94

Staphylococcal Infections Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Staphylococcal Infections Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Staphylococcal Infections Therapeutics market. The report identifies the key trends shaping and driving the global Staphylococcal Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Staphylococcal Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Staphylococcal Infections Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Staphylococcal Infections Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Staphylococcal Infections Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Staphylococcal Infections Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Staphylococcal Infections Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Staphylococcal Infections Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Staphylococcal Infections Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Staphylococcal Infections Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Staphylococcal Infections Therapeutics – Introduction
2.1 Overview
2.2 Pathophysiology
2.3 Epidemiology
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Treatment and Management Pattern
2.8 Report Guidance
3 Staphylococcal Infections Therapeutics – Market Characterization
3.1 Staphylococcal Infections Therapeutics Global Market Size (2005-2010)
3.2 Staphylococcal Infections Market Forecast (2010-2017) – Global
3.3 Staphylococcal Infections Therapeutics Market (2005-2010) – The US
3.4 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – The US
3.5 Staphylococcal Infections Therapeutics Market (2005-2010) – France
3.6 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – France
3.7 Staphylococcal Infections Therapeutics Market (2005-2010) – Germany
3.8 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) - Germany
3.9 Staphylococcal Infections Therapeutics Market (2005-2010) – Spain
3.10 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – Spain
3.11 Staphylococcal Infections Therapeutics Market (2005-2010) – Italy
3.12 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – Italy
3.13 Staphylococcal Infections Therapeutics Market (2005-2010) – The UK
3.14 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – The UK
3.15 Staphylococcal Infections Therapeutics Market (2005-2010) - Japan
3.16 Staphylococcal Infections Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the Staphylococcal Infections Market
3.17.1 Staphylococcal Infections Therapeutics Market Drivers
3.17.2 Staphylococcal Infections Therapeutics Market Barriers
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Staphylococcal Infections Therapeutics – Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Market Products in the Staphylococcal Infections Market
4.3.1 Vancomycin
4.3.2 Zyvox (linezolid)
4.3.3 Cubicin (daptomycin)
4.3.4 Vibativ (televancin)
4.3.5 Tygacil (tigecycline)
4.3.6 Synercid (qinupristin+dalfopristin)
4.3.7 Teflaro (Ceftaroline)
4.4 Staphylococcal Infections Therapeutics – Major Marketed Products Comparison
4.5 Key Takeaway
5 Staphylococcal Infections Therapeutics – Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Staphylococcal Infections Therapeutics Market – Pipeline Assessment by Phase of Development
5.3.1 Staphylococcal Infections– Phase III Pipeline
5.3.2 Staphylococcal Infections Therapeutics Market – Phase II Pipeline
5.3.3 Staphylococcus Infections Therapeutics Market – Phase I Clinical Pipeline
5.3.4 Staphylococcal Infections Therapeutics Market – Preclinical Pipeline
5.3.5 Staphylococcal Infections Therapeutics Market – Discovery Pipeline
5.4 Staphylococcal Infections Therapeutics – Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Staphylococcal Infections Market – Most Promising Drugs under Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 Torezolid phosphate (TR-701, DA-7218)
5.8 Monoclonal antibodies in the Late Stage of Development for Staphylococcal Infections
5.8.1 Pagibaximab (PMAB, BSYX-A110)
5.8.2 Aurexis (tefibazumab)
5.9 Late Stage Molecules under FDA Review
5.10 Key Takeaway
6 Staphylococcal infections Therapeutics – Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials
7 Staphylococcal Infections Therapeutics – Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Staphylococcal Infections Therapeutics – Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Takeda Pharmaceutical Company Limited
8.2.2 Merck & Co., Inc.
8.2.3 Basilea Pharmaceuticals
8.2.4 Forest Laboratories
8.2.5 The Medicines Company
8.2.6 Nabriva Therapeutics AG
8.2.7 TrioBiotics Pharma AG
8.2.8 Inhibitex, Inc.
8.2.9 Biosynexus Incorporated
8.2.10 AstraZeneca PLC
8.2.11 GlaxoSmithKline plc
8.2.12 e-Therapeutics plc
8.2.13 Tabular Presentation Details of Other Companies in the Pipeline
8.3 Key Takeaway
9 Staphylococcal Infections Therapeutics – Licensing & Partnership Deals
10 Staphylococcal Infections Therapeutics: Appendix
10.1 Market Definitions
10.2 Acronyms
10.2.1 Coverage
10.2.2 Secondary Research
10.2.3 Forecasting
10.2.4 Primary Research
10.2.5 Expert Panel Validation
10.3 Contact Us
10.4 Disclaimer
10.5 Bibliography

1.1 List of Tables
Table 1: Staphylococcal Infections Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 2: Staphylococcal Infections Therapeutics, Major Market, Global, Forecast ($bn), 2010–2017
Table 3: Staphylococcal Infections Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 4: Staphylococcal Infections Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 5: Staphylococcal Infections Therapeutics, France, Revenue ($m), 2005–2010
Table 6: Staphylococcal Infections Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 7: Staphylococcal Infections Therapeutics, Germany, Revenue ($m), 2005–2010
Table 8: Staphylococcal Infections Therapeutics Market, Germany , Forecasts ($m), 2010–2017
Table 9: Staphylococcal Infections Therapeutics, Spain, Revenue ($m), 2005–2010
Table 10: Staphylococcal Infections Therapeutics Market, Spain , Forecasts ($m), 2010–2017
Table 11: Staphylococcal Infections Therapeutics, Italy, Revenue ($m), 2005–2010
Table 12: Staphylococcal Infections Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 13: Staphylococcal Infections Therapeutics, The UK, Revenue ($m), 2005–2010
Table 14: Staphylococcal Infections Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 15: Staphylococcal Infections Therapeutics, Japan, Revenue ($m), 2005–2010
Table 16: Staphylococcal Infections Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 17: Major Marketed Products Comparison in Staphylococcal Infections Therapeutics Market, 2011
Table 18: Staphylococcal Infections Therapeutics – Phase III Pipeline, 2011
Table 19: Staphylococcal Infections Therapeutics – Phase II Pipeline, 2011
Table 20: Staphylococcal Infections Therapeutics – Phase I Pipeline, 2011
Table 21: Staphylococcal Infections Therapeutics – Preclinical Pipeline, 2011
Table 22: Staphylococcal Infections Therapeutics – Discovery Pipeline, 2011
Table 23: Staphylococcal Infections Therapeutics Market – Most Promising Drugs Under Clinical Development, 2011
Table 24: Comparison of linezolid and torezolid
Table 25: Development Status of Ceftobiprole
Table 26: Development status of Delbavancin
Table 27: Development status of Iclaprim
Table 28: Staphylococcal Infections Therapeutics – Clinical Trials by Country, 2011
Table 29: Staphylococcal Infections Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Table 30: Staphylococcal Infections Therapeutics, Major Markets, Clinical Trials by Development Status, 2011
Table 31: Staphylococcal Infections Therapeutics, Major Markets, Prominent Sponsors, 2011
Table 32: Staphylococcal Infections Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2011
Table 34: Takeda Pipeline Products 2011
Table 36: Merck Pipeline Products 2011
Table 38: Basilea Pipeline Products 2011
Table 40: Forest Pipeline Products 2011
Table 42: The Medicine Company Pipeline Products 2011
Table 44: Nabriva Pipeline Products 2011
Table 46: TrioBiotics Pipeline Products 2011
Table 40: Inhibitex, Pipeline Overview
Table 48: Astrazeneca Pipeline Products 2011
Table 50: GlaxoSmithKline Pipeline Products 2011
Table 52: e-Therapeutics Pipeline Products 2011
Table 53: Staphylococcal Infections Therapeutics – Other Companies in the Pipeline, 2011
Table 54: Staphylococcal Infections Therapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: Treatment and Management Pattern for Staphylococcal Infected Outpatients
Figure 2: Staphylococcal Infections Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 3: Staphylococcal Infections Therapeutics Market, Global, Forecast ($bn), 2010–2017
Figure 4: Staphylococcal Infections Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 5: Staphylococcal Infections Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 6: Staphylococcal Infections Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 7: Staphylococcal Infections Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 8: Staphylococcal Infections Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 9: Staphylococcal Infections Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 10: Staphylococcal Infections Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 11: Staphylococcal Infections Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 12: Staphylococcal Infections Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 13: Staphylococcal Infections Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 14: Staphylococcal Infections Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 15: Staphylococcal Infections Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 16: Staphylococcal Infections Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 17: Staphylococcal Infections Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 18: Opportunity and Unmet Need in the Staphylococcal Infections Therapeutics Market
Figure 19: Strategic Competitor Assessment
Figure 20: Staphylococcal Infections Therapeutics – Clinical Pipeline by Mechanism of Action, 2011
Figure 21: Staphylococcal Infections Therapeutics Market – Pipeline by Phase of Development, 2011
Figure 22: Technology Trends Analytics Framework, 2011
Figure 23: Technology Trends Analytics Framework – Description, 2011
Figure 24: Staphylococcal Infections Therapeutics – Clinical Trials by Country, 2011
Figure 25: Staphylococcal Infections Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Figure 26: Staphylococcal Infections Therapeutics, Major Markets, Clinical Trials by Development Status, 2011
Figure 27: Staphylococcal Infections Therapeutics, Major Markets, Prominent Sponsors, 2011
Figure 28: Staphylococcal Infections Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2011
Figure 29: Staphylococcal Infections Therapeutics Market, Drivers and Restraints 2011
Figure 30: Implications for Future Market Competition in the Staphylococcal Infections Therapeutics Market, 2011
Figure 31: Staphylococcal Infections Therapeutics Market – Clinical Pipeline by Company, 2011
Figure 32: Market Forecasting Model

Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Basilea Pharmaceuticals
Forest Laboratories
The Medicines Company
Nabriva Therapeutics AG
TrioBiotics Pharma AG
Inhibitex, Inc.
Biosynexus Incorporated
AstraZeneca PLC
GlaxoSmithKline plc
e-Therapeutics plc

Customers who bought this item also bought

• Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
• Disinfectants - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Sepsis Therapeutics - Global Strategic Business Report
• Hospital-Acquired Infection Incidence - Trends in Australia
• Molecular Diagnostics - Global Strategic Business Report
• Blood Banking And Blood Products - Global Strategic Business Report